Chipscreen Biosciences has laid out a number of R&D projects with differentiated advantages and global competitiveness around the five major areas of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals, and stocked a series of candidate drugs, such as CS12088 and CS23074, which are new molecular entities discovered exclusively. These projects/products will also form the core value of Chipscreen Biosciences in the future.

Please scan the QR code below by Wechat and follow the official accounts platform of "Chipscreen Biosciences"to get more information about the latest R&d progress.